Anti-coxsackie medicament composition and medicine use thereof

A coxsackie virus and anti-coxsackie technology, which can be applied in drug combinations, antiviral agents, medical preparations containing active ingredients, etc., can solve problems that have not been seen before

Inactive Publication Date: 2008-12-17
KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the prior art, there is no research report on the use of dammarane-type tetracyclic triterpenoids ginsenoside Rh4 or 20(S)-protopanaxatriol for the treatment of viral myocarditis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-coxsackie medicament composition and medicine use thereof
  • Anti-coxsackie medicament composition and medicine use thereof
  • Anti-coxsackie medicament composition and medicine use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Extraction, isolation and structural identification of two active compounds, ginsenoside Rh4 and 20(S)-protopanaxatriol:

[0027] 5kg Panax notoginseng was purchased in Yunnan, crushed into granules, wrapped with double gauze, placed in a pressure cooker, controlled at a high temperature of 120°C, and steamed for 12 hours to obtain cooked Panax notoginseng. The cooked notoginseng was reflux extracted with industrial ethanol (5L×4), and the solvent was recovered under reduced pressure and concentrated to obtain a total extract of 778g. Dissolve the extract in water, perform column chromatography with D101 macroporous adsorption resin (90×8.5 cm), first elute with water until the Molish reaction of the effluent is negative, and then elute with industrial methanol to obtain 440 g of crude saponin.

[0028] The crude saponin was mixed with about 500 g of silica gel (200-300 mesh), and subjected to dry column chromatography on silica gel (200-300 mesh), using chloroform-meth...

Embodiment 2

[0037] Toxicity determination test of ginsenoside Rh4(1) and 20(S)-protopanaxatriol on Hela cells:

[0038] After Hela cells were digested with trypsin, they were added to a 96-well culture plate, 100 μL / well. After the cells grew into a monolayer, the growth medium was discarded, and 100 μL of maintenance solution containing samples was added to each well. Four replicate wells were set for each dilution. Set normal cell control group, set 5% CO 2 Cultivate in an incubator at 37°C, observe the changes of cells every day, and calculate the maximum non-toxic concentration TC of the drug 0 .

[0039] Results The maximum non-toxic concentration TC of ginsenoside Rh4 and 20(S)-protopanaxatriol on Hela cells 0 50μg / mL, no obvious toxic effects.

Embodiment 3

[0041] Anti-CVB3 virus pharmacodynamic experiment of ginsenoside Rh4(1) and 20(S)-protopanaxatriol:

[0042] Hela cells were cultured in a 96-well plate to a monolayer, the growth medium was discarded, and the samples were diluted to six concentrations (within the maximum non-toxic range of the sample) with the maintenance solution, and 50 μL of the sample maintenance solution and virus dilution solution were added to each well, Set up 4 duplicate wells for each concentration, set up positive control group, virus control group and normal cell control group at the same time, set 5% CO 2 Cultivate in an incubator at 37°C, and observe the condition of cytopathic changes (CPE) every day. When the cytopathy of the virus control group reaches 75% and above and the normal cell control group is normal, observe and record the CPE of each well, use the MTT method to detect the inhibition rate of the sample to the virus, and calculate the half inhibitory concentration (IC) of the sample ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition with dammarane-type tetracyclic triterpene compound ginsenoside Rh4 as shown in the following structural formula and 20(S)-protopanaxatriol as the active components and the application thereof to the pharmaceutical field. The in vitro pharmacological experiments show that the pharmaceutical composition has good in vitro inhibitory activity for coxsackie B3 virus and can be used for treating viral myocarditis caused by coxsackie B3 virus.

Description

technical field [0001] The invention belongs to the field of pharmaceutical compositions, and in particular relates to a pharmaceutical composition in which dammarane-type tetracyclic triterpenoids ginsenoside Rh4 or 20(S)-protopanaxatriol are active ingredients, which are used in the preparation of coxsackie Virus B3 and its application in preparing medicine for treating viral myocarditis caused by Coxsackie virus B3 infection. Background technique [0002] Coxsackieviruses are positive-strand RNA viruses belonging to the family Picornaviridae and the genus Enterovirus. According to their biological characteristics, they can be divided into type A and type B. Coxsackie virus type B infection causes characteristic infectious sternocostal pain, which may be combined with meningoencephalitis, myocarditis, and hepatitis. [0003] Viral myocarditis is mainly caused by Coxsackie virus B3 (CVB3) infection. It is a common cardiovascular disease with a high incidence in all age gro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K31/575A61P31/12A61P29/00
Inventor 张颖君王一飞廖彭莹裴赢杨崇仁王东
Owner KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap